… Vitamin K antagonists were the only class of oral anticoagulants available to clinicians for …
of new oral anticoagulants, such as dabigatran, rivaroxaban, and apixaban, clinicians now …

Direct oral anticoagulants (DOACs) are a more manageable alternative than vitamin K … clinical
practice, there are still some unresolved issues on optimizing their use in particular clinical …

… The complexities of oral anticoagulation with warfarin have … States, the future of oral
anticoagulant therapy will allow a … , cannot quantify the degree of anticoagulant present, and are …

… that direct oral anticoagulants (DOACs) are the cornerstone of anticoagulant strategy in …
, several issues should be considered in clinical practice, including drug–drug interactions (DDIs)…

The introduction of direct oral anticoagulants (OACs) for the treatment and prevention of
thromboembolic disease represents a shift from the traditional vitamin K antagonist-based …

… therapeutic monitoring when required; the aPTT, thrombin time (TT) and ecarin clotting time
(ECT) (not widely available in clinical practice) may all be useful in determining the level of …

OBJECTIVE: This article serves as a resource for health care professionals by providing a
summary of primary literature and guidelines for use of the available oral anticoagulant agents…

… clinical practice. … clinical trials will actually translate into their everyday practice. As a result,
there is a pressing need for convenient new, well-tolerated and effective oral anticoagulants …

… anticoagulation therapy was convened to develop practical strategies for managing patients
receiving oral anticoagulants … The strategies were designed to guide clinicians in the acute …

Introduction: Direct oral anticoagulants (DOACs) may be regarded as some of the most
successful innovations in recent times. These drugs which were specifically developed to …